xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

631

Orlandi et al.

Statistically significant differences favoring steroid at 3 weeks: LKES, 0.53 vs 1.31 ( p < 0.0001) and POSE, 1.21 vs 1.95 ( p = 0.004).

SNOT-22 Statistically significant difference with larger improvement in azithromycin group, but difference (4.2) was smaller than MCID of ∼ 9. Polyp recurrence rate. Disease-free interval. No differences between groups.

No significant differences in endoscopy score or SNOT-22, NOSE, or VAS at 6 weeks.

No difference in symptom or endoscopy outcomes.

No statistically significant difference between groups for any outcome measure.

Statistically significant difference favoring hypertonic irrigation, but differences are likely not clinically significant.

No difference in primary outcomes. Only difference noted in secondary outcomes was statistically significant difference favoring erythromycin at 3 month interval; at 6

months there was no difference, and at the 3 month interval the clinical significance of the difference was questionable.

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Gyawali 2258 2019 2 Single-institution, prospective, blinded RCT(n = 58)

Lund-Kennedy endoscopy score. SNOT-22, NOSE, and VAS for symptoms.

NOSE, SNOT-22, LK endoscopy score

Rawal 1588 2015 2 Prospective, single-center RCT(n = 42) Homemade saline irrigations (n = 18) vs homemade saline plus budesonide 0.5 mg (n = 24) RSOM, RSDI, and SNOT-22 scores UPSIT

Nonstandard symptom score at 1 month

Nonstandard endoscopic score at 1month

Lund-Kennedy endoscopic score (LKES).

Perioperative sinus endoscopy score (POSE). Both assessed at 3 weeks.

Haxel 1116 2015 2 Prospective, single-center RCT(n = 58) Erythromycin 250 mg daily (n = 29) vs placebo (n = 29) for 2 months; Eosinophilic cationic protein; myeloperoxidase in nasal mucus.

Endoscopy score, saccharin transit time, olfaction, SNOT-20, VAS. All at 3 & 6 months

Amali 1115 2015 2 Prospective, single-center RCT(n = 60) Azithromycin 250 mg daily (n = 20) vs placebo (n = 40) for 12 weeks; Brescia 2259 2015 4 Sequential,

Ayoub 2261 2018 2 Prospective, single-center RCT(n = 39) Blew nose BID for 1 week (n = 20) vs no nose blowing (n = 19) for 1

Mozzanica 2260 2019 2 Prospective, multi-center, double-blind RCT (n = 56) Saline irrigation BID (n = 30) vs saline + 9 mg Na Hyaluronate BID(n = 26), both for 6 weeks.

Peric 2254 2019 2 Prospective, single-center RCT(n = 30) 2.3% NaCl seawater (n = 15) vs normal saline (n = 15) Patients with AERD

methylprednisone taper twice a year (2011, n = 28), follow-up at least 3 years.

Daily topical steroid spray(2009-10, n = 32) vs Daily topical steroid spray plus 20 day oral

week; then both groups nose blowing prn

Triamcinolone impregnated PVA pack vs saline impregnated PVA

pack, on opposite side. Other side (randomized) on each patient was control. Both removed at 2 days. No topical steroids until week 3.

both groups received standard postop therapy

both groups received standard postop therapy

comparative study (n = 60). Pts with

non-randomized, single-center

eosinophilic polyps.

TABLE XII-26 (Continued)